Introduction: Licensing as the Lifeblood of Biopharmaceutical Innovation In biopharmaceutical innovation the drug patent licensing agreement stands as the central,
The Strategic Playbook for Identifying and Securing Drug Patent Licensing Opportunities Read Post »
A practitioner’s guide for pharmaceutical analysts, generics strategists, and investors who need to know when a drug is actually off-patent.
Beyond the API: Mapping the Secondary Patent Thicket to Forecast Generic Entry Read Post »
In the multi-trillion-dollar pharmaceutical industry, there’s an attic. It’s filled not with dust and forgotten relics, but with something far
No Patents, No Problem: The Untapped Power of Drug Repurposing Read Post »
Day one of generic competition is the moment most specialty pharmacies dread. The brand rep stops calling. The PBM’s preferred
Double Your Specialty Pharmacy Margins the Day Generics Launch Read Post »
When Pfizer launched atorvastatin (Lipitor) in 1997, it did not simply sell a cholesterol drug. It built, over the next
Defend Your Blockbuster Drug. Here’s the Playbook. Read Post »
Introduction: The Allure of the Biotech Lottery: Beyond the Hype Scan the financial headlines on any given day, and you’re
In the spring of 2014, a small biotech called Idenix Pharmaceuticals held patents covering certain nucleotide analogue structures with antiviral
How Drug Patent LOE forecasting gives equipment suppliers a 24-month head start on their competitors Every year, branded pharmaceutical companies
Drug Patent Cliffs Tell You Who Needs a New Tablet Press Read Post »
The Question Nobody Answers Clearly Ask a pharmaceutical executive how long a drug patent lasts in Latin America and you
Know Your Clock: The Complete Latin American Guide to Drug Patent Duration Read Post »
Sign in or create a free account to read this DrugPatentWatch article
